Compare ISTR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISTR | RCEL |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 403.3M |
| IPO Year | 2014 | 2018 |
| Metric | ISTR | RCEL |
|---|---|---|
| Price | $27.08 | $15.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $33.58 | $20.63 |
| AVG Volume (30 Days) | 61.2K | ★ 564.3K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | 4.41 | ★ 27.20 |
| EPS | ★ 2.11 | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | $62.26 | $33.70 |
| Revenue Next Year | $4.82 | $23.47 |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $23.52 | $3.22 |
| 52 Week High | $31.27 | $18.43 |
| Indicator | ISTR | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 53.70 |
| Support Level | $26.47 | $14.67 |
| Resistance Level | $29.06 | $16.90 |
| Average True Range (ATR) | 0.63 | 1.39 |
| MACD | -0.04 | -0.20 |
| Stochastic Oscillator | 13.89 | 33.78 |
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashier's checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.